157,296 results on '"Liver diseases"'
Search Results
402. DILIN - Prospective Study
403. Role of Immune System in Obesity-related Inflammation and Cardiometabolic Risk
404. Motivational Interviewing in the Management of Non Alcoholic Fatty Liver Disease
405. A Study to Compare How the Study Medicine (PF-07923568) is Processed in Participants With Different Levels of Loss of Liver Function to Healthy Participants.
406. Pirfenidone and Advanced Liver Fibrosis. (PROMETEO)
407. The Impact of Different Exercise Modes on Bile Acid Levels and Liver Function in Patients With Non-alcoholic Fatty Liver Disease
408. Semaglutide in Nonalcoholic Fatty Liver Disease
409. AGED Diagnostics Liver Disease Assessment (AGEDDX)
410. Integrated Multi-omics Data for Personalized Treatment of Obesity-associated Fatty Liver Disease
411. Non-Invasive Diagnostic Tests for MASLD in Pediatric Population
412. Safety Study of Cenobamate in Subjects With Normal Hepatic Function and Subjects With Severe Hepatic Impairment
413. Implementation of a Digital Clinic for Alcohol-associated Liver Disease and Alcohol Use Disorder (DALC) (DALC)
414. Validate the Difficulty Scoring System and Develop a Novel Scoring System for Laparoscopic and Robotic Liver Resections
415. Safety and Efficacy of Endoscopic Ultrasound-Guided Portal Pressure Gradient Measurement
416. Integrated Diagnostics for Early Diagnosis of Liver Disease (ID LIVER)
417. Enhancing Alcohol Treatment Engagement in Associated Liver Disease (ALD) Patients
418. Clinical Characteristics of Metabolic Associated Fatty Liver Disease
419. Risk Factors and Impact MASLD in Patients With IBD (MASLD)
420. Fontan Associated Liver Disease
421. Motorized Fine Needle Biopsy vs Standard Needles
422. IMProving DRug Dosing and Outcomes for Single VEntricle Patients With Fontan Associated Liver Disease (IMPROVE-FALD)
423. Impact of Glycemic Control After Reperfusion on Acute Kidney Injury in Living Donor Liver Transplantation
424. Study to Evaluate the Pharmacokinetics (PK) of E7090 (Herein Referred to as Tasurgratinib) and Its Metabolite in Participants With Mild and Moderate Hepatic Impairment Compared to Healthy Participants
425. Dose Exploration Study of GSK4532990 in Participants With NASH or Suspected NASH (SKYLINE)
426. Knockdown of HSD17B13 mRNA, Pharmacokinetics, Safety, and Tolerability, of AZD7503 in Non-Alcoholic Fatty Liver Disease
427. Liver Steatosis in Pediatric CD Patients
428. A Study of NST-6179 in Adult Subjects With Intestinal Failure-Associated Liver Disease (IFALD).
429. A Study to Evaluate the Safety and Tolerability of Maralixibat in Infant Participants With Cholestatic Liver Diseases Including Progressive Familial Intrahepatic Cholestasis (PFIC) and Alagille Syndrome (ALGS). (RISE)
430. Biobank for Cholestatic Liver Diseases.
431. A Randomized Controlled Trial of an Advanced Care Planning Video Decision Support Tool for Patients With End-Stage Liver Disease
432. Phase 2b Study of GSK4532990 in Adults With NASH (HORIZON)
433. Albumin Modifications as Early Biomarkers of Chronic Liver Diseases (MALAHBAR)
434. Study to Investigate Hepatic Impairment on PK, Safety, Tolerability of Camizestrant in Post-Menopausal Female Subjects
435. Comparison Between 2-dose Versus 3-dose Regimens of Heplisav B in Cirrhosis
436. Cold-induced Brown Fat Activation and Hepatic Steatosis
437. Extracellular RNA Markers of Liver Disease and Cancer
438. Liver Disease, Myocardial Fibrosis and Collaterals in the Adult Fontan Patient a Metabolomics and Proteomics Approach
439. Efficacy and Safety of Herombopag in Patients With Thrombocytopenia Before Hepatectomy
440. Postprandial Lipotoxicity and Nonalcoholic Fatty Liver Disease (LITONAS)
441. Safety Study to Evaluate the Occurrence of EFAD in Pediatric Patients With PNAC Who Require More Than Eight Weeks of Omegaven Treatment
442. Intermittent Fasting for NAFLD in Adults
443. Study of IV VTS-270 for Infantile Liver Disease Associated With Niemann-Pick Disease, Type C
444. Achieving Portal Access With Scorpion Post-Approval Study (APASS)
445. An Open Label, Single-dose, Single Period ADME Study of A4250 in Healthy Subjects
446. A Safety and Pharmakokinetic Study of A4250 Alone or in Combination With A3384
447. Lenvatinib Combined Anti-PD1 Antibody for the Advanced Hepatocellular Carcinoma
448. Impact of FMT on the Phenome in Patients With NAFLD and Fibrosis
449. Strategic Treatment Reduction in Very Early Liver Disease With 4 Weeks Sofosbuvir Plus Glecepravir-pibrentasvir (STRIVE-4)
450. A Multiple Ascending Dose Study of Pegozafermin in Participants With Biopsy Confirmed Nonalcoholic Steatohepatitis (NASH) or Nonalcoholic Fatty Liver Disease (NAFLD) and at High Risk of NASH
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.